Recent biotechnological advances have fuelled development bispecific antibodies (bsAbs) in the last 10 years. However, the functional analysis of bsAbs during bioprocessing adds a challenge for scientists given the array of bsAbs populated by many different species, comprising many different formats, and that traditional SPR and ELISA methods for bsAbs evaluation are time consuming. Furthermore, cell line screening during bsAb production is based only on Protein A titer, where good pools and clone candidates might be discarded given the many antibody conformations that can be produced by cells.
This Sartorius application note describes the development of a simply designed high-throughput bsAb quantitative assay. The novel developed Bio-Layer Interferometry (BLI) assay has been created to offer an easy screening method and workflow that allows: rapid screening of cell lines expressing the target bsAb; faster identification of pools and clones with higher concentrations of bispecific antibodies; assessment of bsAb interactions in a versatile, label-free, and easy-to-use format, and minimal time, effort, and costs in the assay development of bispecific therapeutics.
Download the application note here